Hasani Fatemeh, Masrour Mahdi, Khamaki Sina, Jazi Kimia, Hosseini Saba, Heidarpour Hadiseh, Namazee Mehrad
Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
J Cell Mol Med. 2025 Jan;29(2):e70337. doi: 10.1111/jcmm.70337.
Pancreatic cancer (PC) remains a significant contributor to global cancer mortality, with limited effective diagnostic and prognostic tools. MicroRNAs (miRNAs) have emerged as promising biomarkers for PC diagnosis and prognosis. A comprehensive literature search was conducted in PubMed, Web of Science, and Scopus. Studies reporting sensitivity, specificity or area under the curve (AUC) for miRNAs in PC diagnosis, as well as hazard ratios (HRs) for survival evaluations, were included. Data extraction and quality assessment followed PRISMA guidelines. Meta-analyses were conducted using appropriate statistical methods. The protocol is registered in PROSPERO. Diagnostic analysis included 290 evaluations, revealing an overall AUC of 0.8226 for PC diagnosis. Subgroup analyses showed varying accuracies, with blood and tissue specimens yielding higher AUC values. Promising miRNAs with AUC values above 0.8 included miR-320, miR-1290, miR-93, miR-25, miR-451, miR-20, miR-21, miR-223 and miR-122. Prognostic analysis encompassed 46 studies, indicating significant associations between miRNA expression and overall survival (OS) and progression-free survival (PFS). The combined HR for studies reporting OS HRs higher than one was 1.7613 (95% CI: 1.5394-2.0152, p < 0.0001; I = 81.7%). Notable miRNAs with prognostic significance included miR-10, miR-21 and miR-221. Studies reporting OS HRs less than one had a pooled HR of 0.6805 (95% CI: 0.5862-0.7901, p < 0.0001; I = 65.4%). MiRNAs hold promise as diagnostic and prognostic biomarkers for PC. Blood and tissue specimens offer superior diagnostic accuracy, and several miRNAs show potential for predicting patient outcomes.
胰腺癌（PC）仍然是全球癌症死亡的一个重要因素，有效的诊断和预后工具有限。微小RNA（miRNA）已成为有前景的胰腺癌诊断和预后生物标志物。我们在PubMed、科学网和Scopus上进行了全面的文献检索。纳入了报告miRNA在胰腺癌诊断中的敏感性、特异性或曲线下面积（AUC）以及生存评估的风险比（HR）的研究。数据提取和质量评估遵循PRISMA指南。使用适当的统计方法进行荟萃分析。该方案已在PROSPERO注册。诊断分析包括290项评估，显示胰腺癌诊断的总体AUC为0.8226。亚组分析显示准确性各不相同，血液和组织标本的AUC值更高。AUC值高于0.8的有前景的miRNA包括miR-320、miR-1290、miR-93、miR-25、miR-451、miR-20、miR-21、miR-223和miR-122。预后分析涵盖46项研究，表明miRNA表达与总生存期（OS）和无进展生存期（PFS）之间存在显著关联。报告OS HR高于1的研究的合并HR为1.7613（95%CI：1.5394 - 2.0152，p < 0.0001；I = 81.7%）。具有预后意义的显著miRNA包括miR-10、miR-21和miR-221。报告OS HR低于1的研究的合并HR为0.6805（95%CI：0.5862 - 0.7901，p < 0.0001；I = 65.4%）。miRNA有望成为胰腺癌的诊断和预后生物标志物。血液和组织标本具有更高的诊断准确性，并且几种miRNA显示出预测患者预后的潜力。
